Oxycodone Hydrochloride
Oral Solution
To Be Discontinued Active (discontinuing) — Day 245
High impact — Sole-source drug with no supply currently available from this manufacturer.
FDA shortage record
- Substance
- Oxycodone Hydrochloride
- Manufacturers / suppliers
-
- Hikma Pharmceuticals USA Inc.
- Hikma Pharmaceuticals USA, Inc.
- Dosage form
- Oral Solution
- Presentation
- Oxycodone Hydrochloride, Oral Solution, 5 mg/5 mL (NDC 0054-0390-41)
- Route(s)
- ORAL
- Therapeutic category
- Analgesia/Addiction
- Package NDC
0054-0390-41- Initially posted
- 09/11/2025
- Days on shortage list
- 245
- Discontinued
- 09/11/2025
- Current FDA status
- To Be Discontinued
- Shortage entries (current dataset)
- 1 record for Oxycodone Hydrochloride
Reason and context
Hikma has permanently discontinued (NDC 0054-0390-41) for the 15 mL bottle configuration. Hikma will continue to distribute Oxycodone Hydrochloride Oral Solution 5 mg/5 mL in the 500 mL bottle (NDC 0054-0390-63).
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 800-631-2174.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
d8e87c66-f872-4e1d-9ade-ef11490af63b). - FDA UNII identifier:
C1ENJ2TE6C. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.